Ikena Oncology
6 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study of IK-595 in RAS- or RAF-altered Advanced Tumors (NCT06270082) | Ikena Oncology | 2023-12-18 |
| Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors (NCT05228015) | Ikena Oncology | 2022-01-07 |
| A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (NCT04682431) | Ikena Oncology | 2020-11-10 |
| A Study of PY314 in Subjects With Advanced Solid Tumors (NCT04691375) | Ikena Oncology | 2020-10-29 |
| A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma (NCT04200963) | Ikena Oncology | 2019-12-18 |
Track Ikena Oncology automatically
Every clearance here is in the API, with alerts when new ones post.